Table 3 ORs and corresponding 95% CIs for NHL by presence of anti-HCV in strata of selected matching variables and HIV-transmission category (Swiss HIV Cohort Study, 1984–2004)

From: Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study

 

NHL cases

Control subjects

 
 

N

(%)

N

(%)

OR (95% CI) a

CD4+ at enrolment (cells μl−1)

 <100

     

Anti-HCV−

54

(76.1)

152

(72.7)

1b

Anti-HCV+

17

(23.9)

57

(27.3)

1.47 (0.47–4.53)

 100–199

     

Anti-HCV−

23

(48.9)

96

(67.6)

1b

Anti-HCV+

24

(51.1)

46

(32.4)

2.04 (0.67–6.20)

 200–499

     

Anti-HCV−

83

(69.2)

240

(67.2)

1b

Anti-HCV+

37

(30.8)

117

(32.8)

0.64 (0.26–1.60)

 ⩾500

     

Anti-HCV−

38

(63.3)

117

(64.6)

1b

Anti-HCV+

22

(36.7)

64

(35.4)

1.06 (0.36–3.15)

Test for heterogeneity

    

χ32=1.49; P=0.68

Age group (years)

 <30

     

Anti-HCV−

50

(60.2)

136

(54.6)

1b

Anti-HCV+

33

(39.8)

113

(45.4)

0.62 (0.24–1.62)

 30–44

     

Anti-HCV−

82

(58.2)

267

(62.8)

1b

Anti-HCV+

59

(41.8)

158

(37.2)

1.04 (0.49–2.21)

 ⩾45

     

Anti-HCV−

66

(89.2)

202

(94.0)

1b

Anti-HCV+

8

(10.8)

13

(6.1)

2.21 (0.73–6.70)

Test for heterogeneity

    

χ22=1.56; P=0.46

Gender

     

 Female

     

Anti-HCV−

26

(50.0)

88

(56.4)

1b

Anti-HCV+

26

(50.0)

68

(43.6)

1.07 (0.34–3.31)

 Male

     

Anti-HCV−

172

(69.9)

517

(70.5)

1b

Anti-HCV+

74

(30.1)

216

(29.5)

1.05 (0.59–1.87)

Test for heterogeneity

    

χ12=0.00; P=0.98

HIV-transmission category

 Intravenous drug users

Anti-HCV−

6

(7.5)

12

(5.0)

1b

Anti-HCV+

74

(92.5)

227

(95.0)

0.37 (0.11–1.22)c

 Men having sex with men

Anti-HCV−

132

(90.4)

341

(96.1)

1b

Anti-HCV+

14

(9.6)

14

(3.9)

2.37 (1.03–5.43)c

 Heterosexuals and others

Anti-HCV−

60

(83.3)

252

(85.4)

1b

Anti-HCV+

12

(16.7)

43

(14.6)

1.02 (0.44–2.36)c

Test for heterogeneity

    

χ22=3.34; P=0.19

  1. anti-HCV=antibodies against hepatitis C virus; HIV=human immunodeficiency virus; NHL=non-Hodgkin's lymphoma; OR=odds ratios; CI=confidence intervals.
  2. Estimated from conditional logistic regression analysis, conditioned on centre, gender, age group, and CD4+ count at enrolment and adjusted for HIV-transmission category and year of enrolment;
  3. bReference category.
  4. cEstimated from unconditional logistic regression analysis, adjusted as in footnote a.
Back to article page